Elixir Pharmaceuticals : enrollment in its final pivotal phase III clinical study of mitiglinide for the treatment of patients with type 2 diabetes

March 25, 2008 – Elixir Pharmaceuticals, Inc., announced that it has completed enrollment in its final pivotal phase III clinical study of mitiglinide for the treatment of patients with type 2 diabetes. The study is expected to be completed during the third quarter of 2008, with data available shortly thereafter. The results from this study will supplement the existing clinical database of more than 4,000 patients to form the basis of the Company's anticipated new drug application (NDA) submissions to the FDA in early 2009 for Glinsuna(TM) (mitiglinide) and a fixed combination product, Metgluna(TM), combining metformin and Glinsuna... [PDF] Elixir Pharmaceuticals' Press Release -